|
HHS Panel for the Prevention and Treatment of Opportunistic Infections in HIV-Exposed and HIV-Infected Children
|
Committee, Work group, Advisory group, or Task Force
|
CDC
|
NICHD, OD/DPCPSI/OAR
|
This committee has the purpose of updating the U.S. Pediatric opportunistic infection prevention and treatment guidelines for HIV-Exposed and HIV-Infected Children and serves as executive secretary. These guidelines are developed by a panel of specialists in pediatric HIV infection and infectious diseases (the Panel on Opportunistic Infections in HIV-Exposed and HIV-Infected Children) from the U.S. government and academic institutions. The Panel is a working group of the Office of AIDS Research Advisory Council. For each OI, one or more pediatric specialists with subject-matter expertise reviews the literature for new information since the last guidelines were published, and then proposes revised recommendations for review by the full Panel. After these reviews and discussions, the guidelines undergo further revision, with review and approval by the Panel, and final review and endorsement by the National Institutes of Health (NIH), Centers for Disease Control and Prevention (CDC), the HIV Medicine Association (HIVMA) of the Infectious Diseases Society of America (IDSA), and the Pediatric Infectious Disease Society (PIDS). The Panel also received input from the American Academy of Pediatrics (AAP).
|
|
HHS Panel on Antiretroviral Guidelines for Adults and Adolescents
|
Committee, Work group, Advisory group, or Task Force
|
CDC, FDA, HRSA
|
NICHD, NIAID, OD/DPCPSI/OAR
|
The Department of Health and Human Services (HHS) Panel on Antiretroviral Guidelines for Adults and Adolescents (the Panel) is a working group of the Office of AIDS Research Advisory Council (OARAC). The primary goal of the Panel is to provide HIV care practitioners with recommendations based on current knowledge of antiretroviral drugs (ARVs) used to treat adults and adolescents with HIV in the United States. The Panel reviews new evidence and updates recommendations when needed. These guidelines include recommendations on baseline laboratory evaluations, treatment goals, benefits of ART and considerations when initiating therapy, choice of the initial regimen for ART-naive patients, ARV drugs or combinations to avoid, management of treatment failure, management of adverse effects and drug interactions, and special ART-related considerations in specific patient populations.
|
|
HHS Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV
|
Committee, Work group, Advisory group, or Task Force
|
CDC, FDA, HRSA
|
NICHD, NIAID, OD/DPCPSI/OAR
|
This committee has the purpose of updating the U.S. Pediatric HIV treatment guidelines and serves as executive secretary. The Department's Panel on Antiretroviral Therapy and Medical Management of HIV-Infected Children (the Panel), a working group of the Office of AIDS Research Advisory Council, reviews new data on an ongoing basis, and provides regular updates to the guidelines. The guidelines are available on the AIDSinfo website. These updated guidelines address the use of combination antiretroviral therapy for HIV-infected infants, children, and adolescents. Guidance on management of adverse events associated with use of antiretroviral drugs in children and a detailed review of information about safety, efficacy, and pharmacokinetics of antiretroviral agents in children is also included.
|
|
HHS Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission
|
Committee, Work group, Advisory group, or Task Force
|
CDC, FDA, HRSA
|
NICHD, NIAID, OD/DPCPSI/OAR
|
Also called 'Recommendations for the Use of Antiretroviral Drugs in Pregnant Women with HIV Infection and Interventions to Reduce Perinatal HIV Transmission in the United States'. These Guidelines update the October 2016 Perinatal Guidelines. The Department of Health and Human Services Panel on Treatment of Pregnant Women Living with HIV and Prevention of Perinatal Transmission (the Panel), a working group of the Office of AIDS Research Advisory Council, develops these guidelines. The guidelines provide health care providers with information for discussion with pregnant women living with HIV infection to enable collaborative, informed decision-making regarding the use of ARV drugs during pregnancy, use of scheduled cesarean delivery to reduce perinatal transmission of HIV, and decision-making around the use of ARV drugs for prophylaxis of infants exposed to HIV. The recommendations in these Guidelines are accompanied by a discussion of various circumstances that commonly occur in clinical practice and the factors that influence treatment considerations. The Panel recognizes that strategies to prevent perinatal transmission and concepts related to management of HIV in pregnant women are rapidly evolving and will consider new evidence and adjust recommendations accordingly. The updated guidelines are available from the AIDSinfo website http://aidsinfo.nih.gov.
|
|
HHS Potential Pandemic Pathogens Care and Oversight Review Group
|
Committee, Work group, Advisory group, or Task Force
|
CDC, FDA, OS
|
OD/OSP, NIAID
|
Evaluates proposed research being considered for Department of Health and Human Services (HHS) funding that is anticipated to create, transfer, or use enhanced potential pandemic pathogen (enhanced PPP)--as defined in the Department of Health and Human Services Framework for Guiding Funding Decisions about Proposed Research Involving Enhanced Potential Pandemic Pathogens (HHS P3CO Framework)--to inform agency funding decisions.
|
|
HHS Privacy Committee
|
Committee, Work group, Advisory group, or Task Force
|
OS
|
OD/OM
|
Coordination of Privacy related activities. HHS recognizes the importance of protecting the personally identifiable information (PII) entrusted to us by millions of members of public and employees alike, and has built a robust privacy program to safeguard this information and ensure that HHS upholds Americans' privacy rights.
|
|
HHS Reproductive Health Care Access Task Force (HHS RATF)
|
Committee, Work group, Advisory group, or Task Force
|
OASH, OCR, ASPE, AHRQ, CDC, HRSA, IHS
|
NICHD, OD
|
Represent NIH on this HHS task force to respond to the restrictions in access to reproductive health services.
|
|
HHS SARS-CoV-2 Assay Development Task orders
|
Committee, Work group, Advisory group, or Task Force
|
BARDA
|
NIAID
|
Assays are being developed, qualified and validated to be shared across government studies
|
|
HHS SARS-CoV-2 Immune Assay Testing of Ph3 clinical samples- Task Order
|
Resource Development
|
ASPR
|
NIAID
|
Coordination of testing of Phase 3 clinical samples from HHS Coordination Operations and Response Element (H-CORE) performers in H-CORE Assays (Microneutralization assay)
|
|
HHS Smoking Cessation Workgroup
|
Committee, Work group, Advisory group, or Task Force
|
CDC
|
NIMHD, NCI
|
Discusses tobacco cessation strategies, opportunities for collaborations among HHS agencies, and the newest evidence around tobacco cessation research.
|